Kusajili – Clinical trials directory

Your research

Specialty: Immunothérapie - Vaccinothérapie - Type: Cancer de la jonction oeso-gastrique - Promoter: Bristol Myers Squibb (BMS)

Bristol Myers Squibb (BMS) Update Il y a 4 ans

Étude CA224-060 : étude de phase 2, randomisée, en ouvert, évaluant un traitement associant le relatlimab (anti-LAG-3) et le nivolumab et une chimiothérapie par rapport à un traitement associant le nivolumab et une chemiothérapie, comme traitement de première ligne, chez des patients ayant un adenocarcinome gastrique et de la jonction oesogastrique. CA224-060 - A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) plus Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment in Patients with Gastric or Gastroesophageal Junction Adenocarcinoma

Country France,
organs Estomac, Cardia (jonction gastro-œsophagienne),
Specialty Immunothérapie - Vaccinothérapie, Chimiothérapie,

Essai ouvert aux inclusions

More information

Bristol Myers Squibb (BMS) Update Il y a 5 ans

CA224-060 - A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) plus Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment in Patients with Gastric or Gastroesophageal Junction Adenocarcinoma CA224-060 - A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) plus Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment in Patients with Gastric or Gastroesophageal Junction Adenocarcinoma

Country France,
organs Estomac, Cardia (jonction gastro-œsophagienne),
Specialty Immunothérapie - Vaccinothérapie, Chimiothérapie,

Essai ouvert aux inclusions

More information

1